Synaffix closes series A round for ADC platform

By Cormac SheridanStaff Writer

Tuesday, February 18, 2014

Synaffix BV closed a series A round to take forward its antibody-drug conjugation (ADC) technology, which offers a fresh take on the problem of ADC heterogeneity. The company, based in Oss, the Netherlands, has not disclosed the scale of the funding round.